Pulnovo Medical, a medical equipment provider, has closed a nearly $100 million Series C financing round co-led by Qiming Venture Partners and Lilly Asia Ventures, with additional support from OrbiMed and Gaorong Capital. The funding was oversubscribed by two times, highlighting strong investor confidence in Pulnovo’s strategy and technology. The proceeds will support global clinical trials, international business expansion, and regulatory initiatives. The company is advancing its Pulmonary Artery Denervation (PADN) technology, a minimally invasive treatment for pulmonary hypertension, which has received FDA Breakthrough Device designation and market approval in China.
Pulnovo plans to use the funds to initiate two FDA trials this year for PH treatment in heart failure patients. The company has expanded internationally, establishing offices in the U.S., Singapore, and multiple locations in China. PADN technology is already commercially available in mainland China, Hong Kong, and Macau, with global clinical trials underway in Portugal, Serbia, Georgia, and Southeast Asia. Investors have expressed confidence in Pulnovo’s potential to bring innovative medical solutions to patients worldwide, reinforcing its position as a key player in interventional treatments for PH and heart failure.
